Charles Schwab
RVPH

Charles Schwab’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Charles Schwab’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-750
Closed -$5.72K – 3526
2025
Q2 		$5.72K Hold
750
– – ﹤0.01% 3494
2025
Q1 		$14.3K Buy
+750
New +$23.6K ﹤0.01% 3468
2023
Q1 		– Sell
-612
Closed -$52K – 3585
2022
Q4 		$52K Buy
+612
New +$46.7K ﹤0.01% 3350

Other funds holding RVPH

DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
ECM
EMC Capital Management Houston, Texas $253M AUM

Charles Schwab's RVPH Position: Q3 2025 in Review

Charles Schwab sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q3 2025, closing a stake of 750 shares — an estimated $5.72K sold.

Charles Schwab first reported a position in RVPH in Q4 2022 and held it in 3 quarters. The position peaked at $52K in Q4 2022. 42 funds tracked by Wall St. Rank hold RVPH as of Q3 2025.

  • Charles Schwab reported no remaining REVIVA PHARMA HLDGS INC position as of Q3 2025 after selling out during the quarter.
  • Charles Schwab sold 750 REVIVA PHARMA HLDGS INC shares in Q3 2025, an estimated $5.72K.
  • Charles Schwab first reported a position in REVIVA PHARMA HLDGS INC in Q4 2022 and held it in 3 quarters.
  • Charles Schwab's REVIVA PHARMA HLDGS INC position peaked at $52K in Q4 2022.
  • 42 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q3 2025.

Based on Charles Schwab's 13F filing for Q3 2025, filed 10 Nov 2025.